ERVK13-1

Across TCGA pan-cancer cohorts, ERVK13-1 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ERVK13-1’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where ERVK13-1 RNA is repressed in tumor relative to normal tissue. In most cancer types ERVK13-1 is over-expressed in tumor, although a few such as THCA and LUSC show the opposite, repressed pattern.

THCA, LIHC, and CHOL are the cancer types where ERVK13-1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ERVK13-1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	II,III,IV	−0.691	<.001	8	view →
LIHC	Female	All	+0.468	<.001	7	view →
CHOL	All	All	+0.944	<.001	3	view →
LUSC	All	All	−0.327	.006	3	view →
UCEC	All	All	−0.546	<.001	2	view →
PRAD	All	All	+0.349	.006	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ERVK13-1–THCA

Open the THCA breakdown →